Mirae Asset Global Investments Co., Ltd. Morphic Holding, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$26.12 - $34.07 $460,573 - $600,756	-17,633 Reduced 91.42%	1,655 $56,000
Q1 2024 May 01, 2024	SELL	$26.64 - $40.31 $119,080 - $180,185	-4,470 Reduced 18.81%	19,288 $678,000
Q4 2023 Jan 24, 2024	BUY	$19.95 - $31.0 $50,792 - $78,926	2,546 Added 12.0%	23,758 $686,000
Q3 2023 Oct 26, 2023	BUY	$21.33 - $59.42 $42,723 - $119,018	2,003 Added 10.43%	21,212 $485,000
Q2 2023 Aug 10, 2023	BUY	$34.33 - $62.11 $167,427 - $302,910	4,877 Added 34.03%	19,209 $1.1 Million
Q1 2023 May 04, 2023	BUY	$26.01 - $48.69 $57,846 - $108,286	2,224 Added 18.37%	14,332 $539,000
Q4 2022 Feb 09, 2023	BUY	$24.14 - $30.37 $10,162 - $12,785	421 Added 3.6%	12,108 $323,000
Q3 2022 Nov 10, 2022	BUY	$22.23 - $33.37 $259,802 - $389,995	11,687 New	11,687 $331,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.